| Source: |
| Type: |
| Also known as CP32. Cysteinyl aspartate specific proteinase-3 (Caspase-3) is a common key protein in the apoptosis and pyroptosis pathways, and when activated, the expression level of tumor suppressor gene Gasdermin E (GSDME) determines the mechanism of tumor cell death. As a key protein of apoptosis, caspase-3 can also cleave GSDME and induce pyroptosis. Loss of caspase activity is an important cause of tumor progression. Many anticancer strategies rely on the promotion of apoptosis in cancer cells as a means to shrink tumors. Crucial for apoptotic function are executioner caspases, most notably caspase-3, that proteolyze a variety of proteins, inducing cell death. Paradoxically, overexpression of procaspase-3 (PC-3), the low-activity zymogen precursor to caspase-3, has been reported in a variety of cancer types. Until recently, this counterintuitive overexpression of a pro-apoptotic protein in cancer has been puzzling. Recent studies suggest subapoptotic caspase-3 activity may promote oncogenic transformation, a possible explanation for the enigmatic overexpression of PC-3. Herein, the overexpression of PC-3 in cancer and its mechanistic basis is reviewed; collectively, the data suggest the potential for exploitation of PC-3 overexpression with PC-3 activators as a targeted anticancer strategy. Caspase 3 is the main effector caspase and has a key role in apoptosis. In many types of cancer, including breast, lung, and colon cancer, caspase-3 expression is reduced or absent. On the other hand, some studies have shown that high levels of caspase-3 expression can be associated with a better prognosis in certain types of cancer, such as breast cancer. This suggests that caspase-3 may play a role in the elimination of cancer cells, and that therapies aimed at activating caspase-3 may be effective in treating certain types of cancer. Procaspase-3 is a apoptotic marker protein. Prognostic significance: • High Cas3 expression: Associated with good prognosis and increased sensitivity to chemotherapy in breast, gastric, lung, and pancreatic cancers. • Low Cas3 expression: Linked to poor prognosis and increased risk of recurrence in colorectal, hepatocellular carcinoma, ovarian, and prostate cancers. |
| 6195- | Cuc, | Cucurbitacins as Potent Chemo-Preventive Agents: Mechanistic Insight and Recent Trends |
| - | Review, | Var, | NA |
| 6202- | Cuc, | Cucurbitacins as potential anticancer agents: new insights on molecular mechanisms |
| - | Review, | Var, | NA |
| 1981- | CUR, | Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity |
| - | in-vitro, | Lung, | NA |
| 6227- | CUR, | Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations |
| - | Review, | Var, | NA |
| 6214- | CUR, | Curcumin Nanoparticles-related Non-invasive Tumor Therapy, and Cardiotoxicity Relieve |
| 6219- | CUR, | Natural Products and Altered Metabolism in Cancer: Therapeutic Targets and Mechanisms of Action |
| - | Review, | Var, | NA |
| 475- | CUR, | Curcumin induces apoptotic cell death in human pancreatic cancer cells via the miR-340/XIAP signaling pathway |
| - | in-vitro, | PC, | PANC1 |
| 472- | CUR, | Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis |
| - | vitro+vivo, | Ovarian, | SKOV3 | - | vitro+vivo, | Ovarian, | A2780S |
| 468- | CUR, | 5-FU, | Gut microbiota enhances the chemosensitivity of hepatocellular carcinoma to 5-fluorouracil in vivo by increasing curcumin bioavailability |
| - | vitro+vivo, | Liver, | HepG2 | - | vitro+vivo, | Liver, | 402 | - | vitro+vivo, | Liver, | Bel7 |
| 479- | CUR, | Curcumin Has Anti-Proliferative and Pro-Apoptotic Effects on Tongue Cancer in vitro: A Study with Bioinformatics Analysis and in vitro Experiments |
| - | in-vitro, | Tong, | CAL27 |
| 462- | CUR, | Curcumin promotes cancer-associated fibroblasts apoptosis via ROS-mediated endoplasmic reticulum stress |
| - | in-vitro, | Pca, | PC3 |
| 461- | CUR, | Curcumin inhibits prostate cancer progression by regulating the miR-30a-5p/PCLAF axis |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | Pca, | DU145 |
| 458- | CUR, | Curcumin suppresses gastric cancer by inhibiting gastrin‐mediated acid secretion |
| - | vitro+vivo, | GC, | SGC-7901 |
| 477- | CUR, | Curcumin induces G2/M arrest and triggers autophagy, ROS generation and cell senescence in cervical cancer cells |
| - | in-vitro, | Cerv, | SiHa |
| 457- | CUR, | Curcumin regulates proliferation, autophagy, and apoptosis in gastric cancer cells by affecting PI3K and P53 signaling |
| - | in-vitro, | GC, | SGC-7901 | - | in-vitro, | GC, | BGC-823 |
| 425- | CUR, | Curcumin inhibits proliferation and promotes apoptosis of breast cancer cells |
| - | in-vitro, | BC, | T47D | - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 447- | CUR, | OXA, | Curcumin reverses oxaliplatin resistance in human colorectal cancer via regulation of TGF-β/Smad2/3 signaling pathway |
| - | vitro+vivo, | CRC, | HCT116 |
| 452- | CUR, | Curcumin downregulates the PI3K-AKT-mTOR pathway and inhibits growth and progression in head and neck cancer cells |
| - | vitro+vivo, | HNSCC, | SCC9 | - | vitro+vivo, | HNSCC, | FaDu | - | vitro+vivo, | HNSCC, | HaCaT |
| 444- | CUR, | Cisplatin, | LncRNA KCNQ1OT1 is a key factor in the reversal effect of curcumin on cisplatin resistance in the colorectal cancer cells |
| - | vitro+vivo, | CRC, | HCT8 |
| 137- | CUR, | Curcumin induces G0/G1 arrest and apoptosis in hormone independent prostate cancer DU-145 cells by down regulating Notch signaling |
| - | in-vitro, | Pca, | DU145 |
| 132- | CUR, | Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells |
| - | in-vitro, | Pca, | PC3 |
| 15- | CUR, | UA, | Effects of curcumin and ursolic acid in prostate cancer: A systematic review |
| - | Review, | Pca, | NA |
| 9- | CUR, | Curcumin Suppresses Malignant Glioma Cells Growth and Induces Apoptosis by Inhibition of SHH/GLI1 Signaling Pathway in Vitro and Vivo |
| - | vitro+vivo, | MG, | U87MG | - | vitro+vivo, | MG, | T98G |
| 167- | CUR, | Curcumin-induced apoptosis in PC3 prostate carcinoma cells is caspase-independent and involves cellular ceramide accumulation and damage to mitochondria |
| - | in-vitro, | Pca, | PC3 |
| 3580- | CUR, | Curcumin Acts as Post-protective Effects on Rat Hippocampal Synaptosomes in a Neuronal Model of Aluminum-Induced Toxicity |
| - | in-vivo, | AD, | NA |
| 4652- | CUR, | Anticancer effect of curcumin on breast cancer and stem cells |
| - | Review, | BC, | NA |
| 2688- | CUR, | Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 2818- | CUR, | Novel Insight to Neuroprotective Potential of Curcumin: A Mechanistic Review of Possible Involvement of Mitochondrial Biogenesis and PI3/Akt/ GSK3 or PI3/Akt/CREB/BDNF Signaling Pathways |
| - | Review, | AD, | NA |
| 6234- | CUSP9, | In Vitro and Clinical Compassionate Use Experiences with the Drug-Repurposing Approach CUSP9v3 in Glioblastoma |
| - | Human, | GBM, | NA |
| 7443- | CYN, | Cynaropicrin, a sesquiterpene lactone, triggers apoptotic cell death in triple negative breast cancer cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MCF7 |
| 7451- | CYN, | Inhibitory effects of cynaropicrin on human melanoma progression by targeting MAPK, NF‐κB, and Nrf‐2 signaling pathways in vitro |
| - | in-vitro, | Melanoma, | A375 |
| 7450- | CYN, | Cynaropicrin Induces Cell Cycle Arrest and Apoptosis by Inhibiting PKM2 to Cause DNA Damage and Mitochondrial Fission in A549 Cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | BEAS-2B |
| 6686- | DAP, | Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer |
| - | in-vivo, | Pca, | NA |
| 6682- | DCA, | QC, | Dichloroacetate and Quercetin Prevent Cell Proliferation, Induce Cell Death and Slow Tumor Growth in a Mouse Model of HPV-Positive Head and Neck Cancer |
| - | in-vivo, | HNSCC, | MEER |
| 4901- | DCA, | Sal, | Dichloroacetate and Salinomycin as Therapeutic Agents in Cancer |
| - | Review, | NSCLC, | NA |
| 1878- | DCA, | 5-FU, | Synergistic Antitumor Effect of Dichloroacetate in Combination with 5-Fluorouracil in Colorectal Cancer |
| - | in-vitro, | CRC, | LS174T | - | in-vitro, | CRC, | LoVo | - | in-vitro, | CRC, | SW-620 | - | in-vitro, | CRC, | HT-29 |
| 1874- | DCA, | Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress |
| - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Ovarian, | MDAH-2774 |
| 1444- | Deg, | Deguelin promotes apoptosis and inhibits angiogenesis of gastric cancer |
| - | in-vitro, | GC, | MKN-28 |
| 6676- | Deg, | Deguelin’s Anticancer Bioactivity: Challenges and Opportunities in Medicinal Chemistry |
| - | Review, | Var, | NA |
| 6674- | Deg, | Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway |
| - | in-vitro, | Lung, | H1975 |
| 6707- | DFC, | Markers of mitochondrial dysfunction during the diclofenac-induced apoptosis in melanoma cell lines |
| - | in-vitro, | Melanoma, | NA |
| 6697- | DFC, | Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS |
| 6663- | DFE, | Nutraceuticals of Phoenix dactylifera L.: Physicochemistry, Nutritional Value and Therapeutic Potential |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 6665- | DFE, | Cytotoxic Effect of Phoenix dactylifera (Iraqi Date) Leaves and Fruits Extracts against Breast Cancers Cell Lines |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | CAL51 | - | in-vitro, | BC, | MCF7 |
| 4455- | DFE, | Ajwa Date (Phoenix dactylifera L.) Extract Inhibits Human Breast Adenocarcinoma (MCF7) Cells In Vitro by Inducing Apoptosis and Cell Cycle Arrest |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | Nor, | 3T3 |
| 1854- | dietFMD, | How Far Are We from Prescribing Fasting as Anticancer Medicine? |
| - | Review, | Var, | NA |
| 1860- | dietFMD, | Chemo, | Fasting-mimicking diet blocks triple-negative breast cancer and cancer stem cell escape |
| - | in-vitro, | BC, | SUM159 | - | in-vitro, | BC, | 4T1 |
| 2270- | dietMet, | Methionine-restricted diet inhibits growth of MCF10AT1-derived mammary tumors by increasing cell cycle inhibitors in athymic nude mice |
| - | in-vivo, | Var, | NA |
| 6290- | DL, | Induction of apoptosis by d-limonene is mediated by a caspase-dependent mitochondrial death pathway in human leukemia cells |
| - | in-vitro, | AML, | K562 | - | in-vitro, | AML, | HL-60 |
| 6269- | DL, | Induction of apoptosis by D-limonene is mediated by inactivation of Akt in LS174T human colon cancer cells |
| - | in-vitro, | CRC, | LS174T |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:42 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid